Applicants:

Stanley M. Crain and Kei-Fei Shen

Appn. No.:

Not Yet Assigned (Cont. of 09/585,517)

Filed

Herewith

Page 5

Γ (φ. 165.

(new) The method of Claim 48/wherein the excitatory opioid

receptor antagonist is naltrexone.

17.

(new) The method of Claim 43, wherein the bimodally-acting opioid

receptor agonist is morphine.

18 🖚.

(new) The method of Claim 41, wherein the bimodally-acting opioid

agonist is morphine and the excitatory opioid receptor antagonist is naltrexone.

19

(new) The method of Claim 4, wherein the bimodally-acting opioid

agonist is morphine and the excitatory opioid receptor antagonist is naltrexone.

REMARKS

No fee is deemed necessary in connection with this Preliminary

Amendment. If any fee is required, authorization is hereby given to charge any such fee

to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN

Attorneys for Applicants

(212) 697-5995

Dated: January 3, 2002

New York, New York

By

Craig J. Arnold

Registration No. 34,287

187164.1

3